Non-Hodgkin Lymphoma (NHL)

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1 Credit / Cardiology, Neurology

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.0 Credit / Oncology, Hematology, Hematologic Cancer

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Hematologic Cancer, Hematology, Oncology

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

More News

FDA | Image credit: wladimir1804 - stock.adobe.com

March 25th 2024

FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL

The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).

Magnified image of a cytokine storm | Image Credit: © nobeastsofierce - stock.adobe.com

March 19th 2024

Bispecific Antibodies Represent DLBCL Treatment Breakthrough

Luke Halpern

Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL).

Photomicrograph of a diffuse large B-cell lymphoma a type of non-Hodgkin lymphoma | Image Credit: DavidALitman - stock.adobe.com

March 15th 2024

Radiotherapy May Boost Survival for Certain Patients With DLBCL

Patients had a lower risk of their diffuse large B-cell lymphoma (DLBCL) progressing if they had consolidative radiotherapy, a new report shows.

Patient in the hospital - Tyler Olson -stock.adobe.com.jpg

March 9th 2024

Predictive Model Can Assess Risk of Febrile Neutropenia in Patients Undergoing Chemotherapy for DLBCL

Luke Halpern

Investigators used a predictive model factoring in lymphopenia, elevated SIL2R level, extranodal involvement, and a positive hepatitis panel to determine risk for febrile neutropenia among patients with diffuse large B-cell lymphoma (DLBCL).

Case study graphic | Image credit: onephoto - stock.adobe.com

February 29th 2024

R-CHOP Leads to Positive Outcome in Rare Case of Collision Lymphoma

The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma - David A Litman - stock.adobe.com

February 28th 2024

Review Highlights Potential for Bispecific Antibodies in DLBCL

Luke Halpern

Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.

Doctor checking an older mans lungs | Image credit: DC Studio-stock.adobe.com

February 23rd 2024

Case of Primary Hepatic DLBCL Following COVID-19 Raises Questions About Possible Links

Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.

Rituximab | Image credit: MQ-Illustrations - stock.adobe.com

February 20th 2024

Cameron Santoro

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

CAR T cell therapy rendering | Image Credit: © AIGen - stock.adobe.com

February 12th 2024

Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL

Gwen Mergian

A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.

February 8th 2024

Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

A scientist working with microfluidic devices | Image credit: Наталья Евтехова - stock.adobe.com

February 4th 2024

Study: Microfluid Platform Can Help Screen Novel DLBCL Therapies

The authors say their 3D model improves on results using traditional 2-dimensional approaches.

stem cell transplant text write on blackboard | Image credit: flytoskyft11 - stock.adobe.com

January 30th 2024

Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

Patient and doctor | Image Credit: © DragonImages - stock.adobe.com

January 26th 2024

Case Report Highlights Case of Distinct DLBCLs in a Single Patient

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

January 25th 2024

What We’re Reading: ACA Sign-Up Surge; Hospitals Fight Climate Change; Secondary Cancers, CAR T Link

AJMC Staff

A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.

Data analytics | Image Credit: NicoElNino - stock.adobe.com

January 24th 2024

In DLBCL, Refining Patient Stratification an Ongoing Project

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

January 22nd 2024

Ibrutinib Plus R-CHOP Cost-Effective for Young Patients With ABC-DLBCL

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found.

Health care costs graphic | Image credit: wladimir1804 – stock.adobe.com

January 19th 2024

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Hayden E. Klein

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

January 12th 2024

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match

Mary Caffrey

January 8th 2024

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

Mary Caffrey

Lymphoma cells | Image credit: LASZLO - stock.adobe.com

September 22nd 2023

Salvage RT Shows Local Control in LBCL After CAR T-Cell Therapy Failure

Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.

Diffuse large B-cell lymphoma | Image credit: David A Litman - stock.adobe.com

September 21st 2023

Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL

Kristi Rosa

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

CT machine | Image credit: MyPixelArtStudios - stock.adobe.com

September 15th 2023

Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL

A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Blood cells | Image credit: Катерина Євтехова - stock.adobe.com

September 7th 2023

Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs

The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.

August 18th 2023

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

August 11th 2023

Axi-Cel Extends Survival vs Standard of Care for R/R LBCL

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

Senior sad man leans on a cane while sitting on sofa: © LIGHTFIELD STUDIOS - stock.adobe.com

August 1st 2023

Despite Novelty, Fluid Overload–Associated LBCL Has Distinguishing Features

Investigators said the fact that their patient was 82 years old was one reason to suspect fluid overload–associated large B-cell lymphoma (LBCL).

Doctor holding in his hands two silicone implants. Female patient trying to touch them: © Yakobchuk Olena - stock.adobe.com

July 31st 2023

Amid Increasing Breast Implant–Related EBV+ DLBCL Cases, Researchers Share Insights on the Disease

Jaime Rosenberg

Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).

Blood vial and hepatitis B | Image Credit: © alexskopje - stock.adobe.com

July 29th 2023

Treated Hepatitis B Infection May Be a Positive Prognostic Factor in Patients With DLBCL

Gianna Melillo

Those with the infection who underwent treatment exhibited improved outcomes compared with patients without the infection.

Endocrinology doctor consulting lymphoma patient with sore neck, aching swollen lymph nodes, throat pain, laryngitis, hodgkin symptoms. Healthcare specialist medical appointment in clinic office: © DC Studio - stock.adobe.com

July 27th 2023

Review Details Current Understanding, Future Directions of DLBCL in Patients With HIV

Gianna Melillo

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype in individuals living with HIV.

July 22nd 2023

In DLBCL Treatment, Cardiovascular Comorbidities Warrant Careful Consideration